Earlier Merck Study Indicated Risks of Vioxx

Article Abstract:

Raymond V. Gilmartin, chief executive officer of pharmaceutical company Merck and Company Inc., will be questioned by the Senate Finance Committee regarding the recall of the Cox-2 inhibitor Vioxx. Although the company had preliminary results from clinical trials suggesting Vioxx posed cardiovascular risks, it was nearly a year before the drug was recalled.

Legal issues & crime, Product standards, safety, & recalls, Product information, Legislative Bodies, Senate-Finance, Company legal issue, Product defects and recalls, Investigations, COX-2 inhibitors, Chief executive officers, United States. Congress. Senate. Committee on Finance, Evidence, Gilmartin, Raymond V.

---

A.M.A. Adds Its Voice to Call For Disclosure On Drug Trials

Article Abstract:

Under-reporting of unfavorable drug trial results has led to calls for a national database in which all trials are registered; pharmaceutical companies argue against its creation , while the American Medical Association and other medical groups support it.

Government domestic functions, Political aspects, American Medical Association, Health policy

---

For Merck, Defense of a Drug Crumbles at a Difficult Time

Article Abstract:

Merck and Company has discontinued the arthritis and pain medication Vioxx because of studies linking it to increased heart disease and stroke risk, prompting industry analysts to question why the decision had taken so long.

Marketing procedures, Product discontinued, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, Marketing, Risk factors, Drug therapy, Heart diseases, Stroke (Disease), Stroke, Arthritis, Company marketing practices, Analgesics, Product discontinuation

Similar abstracts:

• Abstracts: Merck Says It Will Post the Results of All Drug Trials. As Doctor Writes Prescription, Drug Company Writes a Check
• Abstracts: Economy Remained Strong In 4th Quarter, U.S. Reports. Deficits and Tax System Changes In Bush's Second-Term Economy
• Abstracts: A Lazard Feud Over an Offering Spills Into View. Mergers Show Steel Industry Is Still Worthy Of Big Deals. Nokia Aims New Models At the Midprice Market
• Abstracts: China and the U.S. Embark on a Perilous Trip. Families, Deep in Debt, Bracing For Pain of Interest Rate Rise. Gas Prices Lead Gradual Rise in Inflation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.